301 related articles for article (PubMed ID: 23404788)
21. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
22. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
23. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
Rosenstock J; Balas B; Charbonnel B; Bolli GB; Boldrin M; Ratner R; Balena R;
Diabetes Care; 2013 Mar; 36(3):498-504. PubMed ID: 23139373
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
[TBL] [Abstract][Full Text] [Related]
25. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
[TBL] [Abstract][Full Text] [Related]
26. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
27. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
28. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
31. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
32. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
33. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
[TBL] [Abstract][Full Text] [Related]
37. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
39. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
40. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
